122001-19-8

Upstream product

• 56983-95-0 2-phenylpyrazolo[1,5-a]pyridine 

Downstream Products

• 1610529-27-5 1-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)urea 
• 122001-26-7 2-phenyl-3-nitro-pyrazolo[1,5-a]pyridine 

Relevant academic research and scientific papers

BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

Method of treating kidney disease using pyrazolopyridine compound

The invention relates to a method for the treatment of renal toxicity, nephrosis or nephritis which comprises administering an effective amount of the pyrazolopyridine compounds of the invention.

Pharmaceutical method of treatment using pyrazolopyridine compound

The invention relates to a method for the treatment of ailments which comprises administering an effective amount of the pyrazolopyridine compounds of the invention.

Pyrazolopyridine compound and processes for preparation thereof

The disclosure deals with pyrazolopyridine compounds of the formula STR1 wherein the variables are defined in the specification. The compounds are useful in the treatment of bronchial asthma, immunosuppression, diabetes, etc.

Pharmaceutically useful pyrazolopyridines

The disclosure deals with a pyrazolopyridine compound of the formula STR1 wherein the variables are defined in the specification. The compounds are useful as a diuretic, antihypertensive agent, etc.